PE Tech Report


Like this article?

Sign up to our free newsletter

Calculus Capital to invest GBP3m in drug developer C4X Discovery

Calculus Capital is to make a GBP3 million investment in drug discovery engine C4X Discovery, becoming a cornerstone investor in a GBP5 million AIM fundraising, scheduled for admission to the market on 27 September.  

The money will be used to progress C4X’s existing pipeline of pre-clinical drug design and development for use in the treatment of a wide range of diseases and medical conditions.
John Glencross, chief executive of Calculus Capital, says: “C4X Discovery aims to become the world’s most productive drug discovery and development company. That is no small ambition but we believe its patented drug discovery platform, Conformetrix, and revolutionary genetic technology, Taxonomy3, mean it has the potential to achieve this goal. 
“C4X’s highly talented and experienced management team, led by Clive Dix, whose track-record in the sector is extremely impressive, instil us with great confidence about the direction and momentum of this business.”
Clive Dix, CEO of C4X Discovery, says: "Calculus Capital is a leading EIS and VCT investor with a strong track record in the healthcare sector. I look forward to welcoming Calculus Capital as a new shareholder. ”
Calculus’s past exits from investments in the healthcare sector include Scancell in 2014, at an exit multiple of 8.2x, Epistem in 2014 at 2x, and, just a few days ago, Horizon Discovery at 1.8x. 

Like this article? Sign up to our free newsletter